This company listing is no longer active
Radius Health Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Información clave
28.6%
Tasa de crecimiento de los beneficios
30.1%
Tasa de crecimiento del BPA
Crecimiento de la industria Biotechs | 17.0% |
Tasa de crecimiento de los ingresos | 35.3% |
Rentabilidad financiera | n/a |
Margen neto | -30.7% |
Última actualización de beneficios | 30 Jun 2022 |
Actualizaciones de resultados anteriores recientes
Recent updates
Radius stock rises as elacestrant gets FDA priority review to treat breast cancer subtype
Aug 11Reevaluating Radius Health
Feb 24Radius Health EPS misses by $0.02, misses on revenue
May 07When Will Radius Health, Inc. (NASDAQ:RDUS) Become Profitable?
Feb 23Revisiting Radius Health
Feb 01Radius Health acquires global rights to RAD011 in Prader-Willi syndrome
Jan 06How Much Did Radius Health's(NASDAQ:RDUS) Shareholders Earn From Share Price Movements Over The Last Five Years?
Jan 01Radius Health on-track for record quarterly revenue for TYMLOS-SC
Dec 15Desglose de ingresos y gastos
Cómo gana y gasta dinero Radius Health. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
---|---|---|---|---|
30 Jun 22 | 223 | -69 | 129 | 121 |
31 Mar 22 | 217 | -73 | 127 | 122 |
31 Dec 21 | 230 | -70 | 130 | 131 |
30 Sep 21 | 228 | -76 | 138 | 128 |
30 Jun 21 | 249 | -60 | 134 | 134 |
31 Mar 21 | 247 | -87 | 140 | 151 |
31 Dec 20 | 239 | -109 | 143 | 159 |
30 Sep 20 | 232 | -113 | 144 | 158 |
30 Jun 20 | 200 | -136 | 148 | 149 |
31 Mar 20 | 191 | -128 | 150 | 131 |
31 Dec 19 | 173 | -133 | 155 | 115 |
30 Sep 19 | 152 | -149 | 163 | 104 |
30 Jun 19 | 133 | -169 | 170 | 100 |
31 Mar 19 | 115 | -203 | 179 | 99 |
31 Dec 18 | 99 | -221 | 186 | 98 |
30 Sep 18 | 72 | -251 | 193 | 97 |
30 Jun 18 | 58 | -259 | 197 | 91 |
31 Mar 18 | 37 | -259 | 199 | 84 |
31 Dec 17 | 22 | -254 | 189 | 81 |
30 Sep 17 | 14 | -236 | 167 | 82 |
30 Jun 17 | 1 | -224 | 138 | 89 |
31 Mar 17 | 0 | -199 | 104 | 97 |
31 Dec 16 | 0 | -183 | 80 | 105 |
30 Sep 16 | 0 | -163 | 62 | 104 |
30 Jun 16 | 0 | -145 | 51 | 95 |
31 Mar 16 | 0 | -125 | 40 | 84 |
31 Dec 15 | 0 | -102 | 31 | 68 |
Ingresos de calidad: RDUS is currently unprofitable.
Margen de beneficios creciente: RDUS is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: RDUS is unprofitable, but has reduced losses over the past 5 years at a rate of 28.6% per year.
Acelerando crecimiento: Unable to compare RDUS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: RDUS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (24.5%).
Rentabilidad financiera
Alta ROE: RDUS's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.